Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Emflaza

- PMLiVE

Sarepta soars as FDA clears its muscular dystrophy drug

Analysts anticipate blockbuster status for DMD therapy despite efficacy concerns

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

- PMLiVE

Snowflakes and fingerprints

No two snowflakes or fingerprints are alike; the same is true of healthcare

UK flag

UK government tables bill on medicine pricing reforms

New scheme proposes single payment mechanism for old and new drugs alike

- PMLiVE

Global pharma market forecast to reach $1.12tr by 2022

Annual growth of 6.3 per cent expected and biologics are set to occupy a stronger position

Summit takes clinical trial participant search online

Hopes to broaden reach of its Duchenne muscular dystrophy study

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

- PMLiVE

Retrophin rockets away as rare disease trial hits targets

Sparsentan has potential to become a blockbuster FSG drug, according to analysts

- PMLiVE

Merck closes in on first-line NSCLC label for Keytruda in US

Accelerated FDA review could see PD-1 inhibitor approved by the end of the year

Roche Basel Switzerland

Roche’s melanoma combo “too expensive” for NHS use, says NICE

Cost-effectiveness body rejects Cotellic/Zelboraf despite acknowledging survival benefits

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links